National Bioproducts Institute NPC (NBI), a South African pharmaceutical company, faced the challenge of modernizing its manufacturing processes to produce a cost-effective 20% immunoglobulin (IgG) solution for subcutaneous administration (SCIG). The conventional process was hindered by the high cost and short lifespan of Heparin Sepharose chromatography resin.
Sartorius BIA Separations provided a solution by evaluating CIMmultus® chromatographic monolithic column chemistries, optimizing process parameters, and successfully demonstrating purification at commercial scale. This collaboration enabled NBI to develop a robust and affordable SCIG manufacturing process, with ongoing efforts to optimize virus reduction and develop a biosimilar therapeutic protein. The scientific advancements were showcased at the 13th International Plasma Product Biotechnology meeting in Dubrovnik, Croatia, in April 2025.
